Quantitative Immunochemical Fecal Occult Blood Test in Symptomatic Patients
NCT ID: NCT02491593
Last Updated: 2018-11-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
242 participants
OBSERVATIONAL
2014-04-30
2017-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Accuracy and Predictive Values for Colorectal Cancer of Quantitative FIT in Symptomatic Patients in Primary Care
NCT05156307
A Prospective Study of a New Immunological Fecal Occult Blood Test
NCT00959491
Faecal Immunochemical Test and Urine Volatile Compounds in Adenoma Detection
NCT04146662
Comparison of Hemoccult, Magstream and OC-Sensor Faecal Occult Blood Tests in Colorectal Cancer Screening
NCT01251666
A Prospective Study of a New Immunochemical Fecal Occult Blood Test in U.S. Veteran Patients Undergoing Colonoscopy
NCT00533975
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Hemoglobin concentration will be notified in the range of 50 - \< 1000 ng/mL, or as a negative outcome.
Macroscopic findings at the colonoscopy will be collected, as well as the outcome of the pathological report.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
fecal occult blood test
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* High-risk patients
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Uppsala University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Louise Olsson, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Centre for Clinical research, Eskilstuna, Uppsala universitet
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Unit of Endoscopy
Eskilstuna, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tsapournas G, Hellstrom PM, Cao Y, Olsson LI. Diagnostic accuracy of a quantitative faecal immunochemical test vs. symptoms suspected for colorectal cancer in patients referred for colonoscopy. Scand J Gastroenterol. 2020 Feb;55(2):184-192. doi: 10.1080/00365521.2019.1708965. Epub 2020 Jan 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
QFecalBlood 2013/2:7
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.